Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared on LinkedIn:
“Our recent publication and 1st in 2026 out in Therapeutic advances in Hematology (IF 3.1)
Avatrombopag in Aplastic Anemia – Review
- Scope: 10 studies (2023–2025), diverse AA settings (frontline, R/R, elderly, liver disease)
- Efficacy: ORR 55–85%; CR up to ~30%
- Onset: Rapid responses, typically within 1–2 months
- Clinical benefit: Multilineage recovery, reduced transfusion needs
- After eltrombopag: Responses seen even in EPAG-refractory/intolerant patients
- Safety: Favorable profile; no meaningful hepatotoxicity or clonal evolution reported
- Key advantage: Suitable for patients with liver dysfunction, no dietary restrictions
Bottom line: Avatrombopag is an effective, well-tolerated TPO-RA with growing role in AA across disease stages”
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri D, Ahmed Kotb Abdrabou, Alfadil Haroon, Hadeel Samarkandi, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari
Read full article here.
Stay updated on the latest scientific advances in the field of aplastic anemia with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal